Current status of therapeutic drug monitoring of 5-fluorouracil prodrugs

Y Hashimoto, Y Yoshida, T Yamada, N Aisu… - Anticancer …, 2020 - ar.iiarjournals.org
In recent years, therapeutic drug monitoring (TDM) of intravenous administration of 5-
fluorouracil (5-FU) has resulted in reduced toxicity and improved efficacy. Prodrugs of 5-FU …

Therapeutic drug monitoring of 5-fluorouracil

JJ Lee, JH Beumer, E Chu - Cancer chemotherapy and pharmacology, 2016 - Springer
Abstract Purpose For over 50 years, 5-FU has played a critical role in the systemic
chemotherapy of cancer patients. 5-FU serves as the main backbone of combination …

Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes

MW Saif, A Choma, SJ Salamone… - JNCI: Journal of the …, 2009 - academic.oup.com
Chemotherapy dosing of the fluoropyrimidine 5-fluorouracil (5-FU) is currently based on
body surface area. However, body surface area–based dosing has been associated with …

The prodrugs of 5-fluorouracil

M Malet-Martino, P Jolimaitre… - … Medicinal Chemistry-Anti …, 2002 - ingentaconnect.com
Although 5-fluorouracil (FU) was first introduced in 1957, it remains an essential part of the
treatment of a wide range of solid tumors. FU has antitumor activity against epithelial …

Drug delivery of oral anti-cancer fluoropyrimidine agents

K Miura, H Shima, N Takebe, J Rhie… - Expert Opinion on …, 2017 - Taylor & Francis
Introduction: Sixty years since its introduction, 5-FU still forms the core of chemotherapy
regimens for many types of malignancies. 5-FU is a time-dependent drug but is rapidly …

Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion

JL Grem, M Quinn, A Ismail, CH Takimoto… - Cancer chemotherapy …, 2001 - Springer
Purpose: Clinical toxicity associated with 5-fluorouracil (5-FU) is related to the area under
the plasma concentration-time curve (AUC). Recently, short-term infusions of 5-FU given …

Pharmacokinetic monitoring with dosage adjustment of 5 fluorouracil administered by continuous infusion

J Wihlm, D Leveque, M Velten, T Klein - Bulletin du cancer, 1993 - europepmc.org
Therapeutic drug monitoring of 5-FU was investigated in patients with head and neck cancer
treated with cisplatin (100 mg/m2) followed by 5-day continuous infusion of 5-FU (1 g/m2/d) …

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and …

R Fety, F Rolland, M Barberi-Heyob, A Hardouin… - Clinical cancer research …, 1998 - AACR
A significant link between 5-fluorouracil (5FU) plasma concentration and its therapeutic
activity has been demonstrated in colon and head and neck cancer patients for 5FU used as …

[HTML][HTML] Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil …

K Freeman, M Connock, E Cummins… - Health technology …, 2015 - europepmc.org
Background 5-Fluorouracil (5-FU) is a chemotherapy used in colorectal, head and neck
(H&N) and other cancers. Dose adjustment is based on body surface area (BSA) but wide …

A review of analytical methods for the determination of 5-fluorouracil in biological matrices

M Breda, S Barattè - Analytical and bioanalytical chemistry, 2010 - Springer
Fluorouracil (5-FU) is a cytostatic agent that has been widely used in the treatment of various
solid tumours for more than 20 years, and is still considered to be among the most active …